Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future

Journal of Hematology & Oncology

Weijing Sun¹  Gaurav Goel¹ 

[1] Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Centre Avenue, Fifth Floor, Pittsburgh 15232, PA, USA

关键词: Biomarkers;    Novel therapies;    Locally advanced pancreatic cancer;    Metastatic pancreatic cancer;    Advanced pancreatic cancer;    Pancreatic ductal adenocarcinoma;   

Others  :  1211898
DOI  :  10.1186/s13045-015-0141-5

 received in 2015-01-21, accepted in 2015-04-21,  发布年份 2015

【 摘 要 】

Despite a few breakthroughs in therapy for advanced disease in the recent years, pancreatic ductal adenocarcinoma continues to remain one of the most challenging human malignancies to treat. The overall prognosis for the majority of patients with pancreatic cancer is rather dismal, and therefore, more effective treatment options are being desperately sought. The practical goals of management are to improve the cure rates for patients with resectable disease, achieve a higher conversion rate of locally advanced tumor into potentially resectable disease, and finally, prolong the overall survival for those who develop metastatic disease. Our understanding of the complex genetic alterations, the implicated molecular pathways, and the role of desmoplastic stroma in pancreatic cancer tumorigenesis has increased several folds in the recent years. This has facilitated the development of novel therapeutic strategies against pancreatic cancer, some of which are currently under evaluation in ongoing preclinical and clinical studies. This review will summarize the existing treatment approaches for this devastating disease and also discuss the promising therapeutic approaches that are currently in different stages of clinical development.

【 授权许可】

   
2015 Goel and Sun; licensee BioMed Central.

【 参考文献 】

• [1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
• [2]Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al.. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321:1801-6.
• [3]Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X et al.. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009; 69:3681-8.
• [4]Genkinger JM, Spiegelman D, Anderson KE, Bergkvist L, Bernstein L, van den Brandt PA et al.. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009; 18:765-76.
• [5]Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB et al.. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013; 145:1449-58.
• [6]Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N et al.. Pancreatic cancer risk and levels of trace elements. Gut. 2012; 61:1583-8.
• [7]Wormann SM, Algul H. Risk factors and therapeutic targets in pancreatic cancer. Front Oncol. 2013; 3:282.
• [8]Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009; 133:365-74.
• [9]Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010; 44:293-311.
• [10]Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I et al.. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013; 62:339-47.
• [11]Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6:2969-72.
• [12]Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000; 156:1821-5.
• [13]Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al.. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467:1114-7.
• [14]Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008; 3:157-88.
• [15]Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol. 1995; 18:1-6.
• [16]di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013; 144:1220-9.
• [17]Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene. 2013; 32:5253-60.
• [18]Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res. 2004; 64:5659-63.
• [19]Sasaki S, Yamamoto H, Kaneto H, Ozeki I, Adachi Y, Takagi H et al.. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep. 2003; 10:21-5.
• [20]Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med. 2009; 133:413-22.
• [21]Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA et al.. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60:861-8.
• [22]Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ et al.. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A. 2009; 106:4254-9.
• [23]Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004; 91:586-94.
• [24]Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362:1605-17.
• [25]Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al.. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304:1073-81.
• [26]Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al.. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350:1200-10.
• [27]Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A et al.. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011; 18:1319-26.
• [28]Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al.. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267-77.
• [29]Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al.. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299:1019-26.
• [30]Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B et al.. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127:1335-9.
• [31]Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS et al.. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998; 16:3843-50.
• [32]Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN et al.. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002; 20:2537-44.
• [33]Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al.. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3496-502.
• [34]Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW et al.. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3487-95.
• [35]Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144:1316-26.
• [36]Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H et al.. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001; 5:27-35.
• [37]Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF et al.. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26:942-7.
• [38]Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE et al.. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011; 18:619-27.
• [39]Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B et al.. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011; 104:155-61.
• [40]Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J et al.. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981; 48:1705-10.
• [41]Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D et al.. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29:4105-12.
• [42]Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC et al.. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol, Biol, Phys. 2003; 57:98-104.
• [43]Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA et al.. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22:3776-83.
• [44]Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al.. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22:1430-8.
• [45]Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T et al.. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23:3509-16.
• [46]Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F et al.. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol. 2007; 30:15-20.
• [47]Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK et al.. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013; 108:236-41.
• [48]Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA et al.. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18:543-8.
• [49]Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM et al.. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013; 30:361.
• [50]Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A et al.. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012; 12:199.
• [51]Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F et al.. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25:326-31.
• [52]Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P et al.. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110:47-55.
• [53]Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-13.
• [54]Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al.. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960-6.
• [55]Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817-25.
• [56]Mahaseth H, Kauh JS, Brutcher E, Hawk NN, Kim S, Chen Z. Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: a retrospective experience. In: ASCO Meeting. 2012.
• [57]Edmonds C, Cengel KA. Tumor-stroma interactions in pancreatic cancer: Will this SPARC prove a raging fire? Cancer Biol Ther. 2008; 7:1816-7.
• [58]Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE et al.. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29:4548-54.
• [59]Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al.. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-703.
• [60]Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17:3631-52.
• [61]Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M et al.. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003; 21:1301-6.
• [62]Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK et al.. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005; 23:485-7.
• [63]Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6:27.
• [64]Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G et al.. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012; 30:1216-23.
• [65]Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM et al.. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014; 50:2072-81.
• [66]Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al.. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011; 25:460-70.
• [67]Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G et al.. The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992; 166:7-12.
• [68]Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L et al.. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001; 24:496-9.
• [69]Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX et al.. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007; 25:4787-92.
• [70]Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J et al.. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004; 22:2610-6.
• [71]Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ et al.. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 28:3605-10.
• [72]Kim GP, Foster NR, Salim M, Flynn PJ, Moore DF, Zon R et al.. Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. J Clin Oncol. 2011; 29(suppl):abstr 4030.
• [73]Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C et al.. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004; 22:706-12.
• [74]Niu FY, Wu YL. Novel agents and strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol. 2014; 3:2.
• [75]Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H et al.. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28:3617-22.
• [76]Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL et al.. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27:2231-7.
• [77]Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C et al.. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008; 371:2101-8.
• [78]Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T et al.. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011; 12:256-62.
• [79]Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C et al.. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013; 49:2633-42.
• [80]Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R et al.. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012; 23:2799-805.
• [81]Deplanque G, Demarchi M, Hebbar M, Flynn PJ, Melichar B, Atkins J et al.. Masitinib in nonresectable pancreatic cancer: results of a phase III randomized placebo-controlled trial. J Clin Oncol. 2013; 31(suppl):abstr 158.
• [82]Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM et al.. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012; 23:2834-42.
• [83]Philip PA, Goldman BH, Ramanathan RK, Lenz H, Lowy AM, Philip PA et al.. Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). J Clin Oncol. 2012; 30 suppl 4:abstr 198.
• [84]Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013; 6:88.
• [85]Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA et al.. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009; 27:193-8.
• [86]Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012; 18:2464-71.
• [87]Farhana L, Dawson MI, Das JK, Murshed F, Xia Z, Hadden TJ et al.. Adamantyl retinoid-related molecules induce apoptosis in pancreatic cancer cells by inhibiting IGF-1R and Wnt/β-catenin pathways. J Oncol. 2012; 2012:796729.
• [88]Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J C ancer. 2005; 41:2620-9.
• [89]Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S et al.. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014; 7:87.
• [90]Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF et al.. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther. 2012; 11:1999-2009.
• [91]Morton JP, Mongeau ME, Klimstra DS, Morris JP, Lee YC, Kawaguchi Y et al.. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2007; 104:5103-8.
• [92]Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK et al.. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62:112-20.
• [93]Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM et al.. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol. 2013; 31(suppl):abstr 4010.
• [94]Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87:161-7.
• [95]Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A et al.. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21:3296-302.
• [96]Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J, Jr., Chiorean EG, Rosen PJ, et al.: Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2014.
• [97]Fuxe J, Karlsson MC. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012; 22:455-61.
• [98]Oettle H, Seufferlein T, Luger T, Schmid RM, Wichert GV, Endlicher E et al.. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol. 2012; 30(suppl):abstr 4034.
• [99]Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69:6539-45.
• [100]Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137:482-8.
• [101]Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012; 18:2905-12.
• [102]Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013; 42:1054-9.
• [103]Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC et al.. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004; 64:5084-8.
• [104]Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998; 17:3351-62.
• [105]Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A et al.. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer. 2002; 32:1-6.
• [106]Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ et al.. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005; 54:254-64.
• [107]Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D et al.. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012; 12:173-80.
• [108]Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D et al.. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007; 52:1964-72.
• [109]Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S et al.. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013; 17:94-100.
• [110]Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M et al.. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006; 95:1474-82.
• [111]Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J et al.. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas. 2012; 41:374-9.
• [112]Wolpin BM, O’Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM et al.. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013; 24:1792-801.
• [113]Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al.. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331:1612-6.
• [114]Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US et al.. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33:828-33.
• [115]Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN et al.. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer. 2012; 118:5497-506.
• [116]Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA et al.. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology. 2012; 143:1095-107.
• [117]Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, Ong A, Wang Y, Yeh G, Chen L. A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2011; 29(suppl):abstr 4069.
• [118]Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H et al.. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol. 2012; 69:1197-204.
• [119]Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M et al.. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 2008; 38:227-9.
• [120]Fukutomi A, Uesaka K, Boku N, Kanemoto H, Konishi M, Matsumoto I et al.. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 2013; 31(suppl):abstr 4008.
• [121]Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S et al.. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66:3928-35.
• [122]Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I et al.. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013; 31:4453-61.
• [123]Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X et al.. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013; 119:173-81.
• [124]Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M et al.. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007; 96:457-63.
• [125]Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT et al.. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012; 13:724-33.
• [126]Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB et al.. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014; 20:5281-9.